Illumina, Inc. (NASDAQ:ILMN) Given Consensus Rating of “Hold” by Brokerages

Shares of Illumina, Inc. (NASDAQ:ILMN) have earned an average recommendation of “Hold” from the twenty-one brokerages that are covering the company, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, fourteen have issued a hold recommendation and five have issued a buy recommendation on the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $118.3125.

ILMN has been the subject of several recent research reports. Canaccord Genuity Group lifted their price objective on Illumina from $112.00 to $130.00 and gave the company a “hold” rating in a report on Monday, December 22nd. JPMorgan Chase & Co. raised their target price on shares of Illumina from $105.00 to $130.00 and gave the company a “neutral” rating in a research report on Monday, December 15th. Barclays boosted their price target on shares of Illumina from $100.00 to $110.00 and gave the company an “underweight” rating in a report on Monday, December 15th. Cowen reaffirmed a “hold” rating on shares of Illumina in a research report on Friday, October 31st. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of Illumina in a report on Monday, December 29th.

Illumina Stock Performance

Shares of NASDAQ:ILMN opened at $134.35 on Monday. The firm’s 50 day simple moving average is $125.81 and its 200-day simple moving average is $107.99. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.12 and a current ratio of 1.43. Illumina has a one year low of $68.70 and a one year high of $153.06. The firm has a market cap of $20.53 billion, a PE ratio of 30.12, a price-to-earnings-growth ratio of 2.24 and a beta of 1.41.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Thursday, October 30th. The life sciences company reported $1.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.16 by $0.18. The company had revenue of $1.08 billion for the quarter, compared to analysts’ expectations of $1.07 billion. Illumina had a return on equity of 29.21% and a net margin of 16.40%.Illumina’s revenue was up .4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.14 earnings per share. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS. As a group, equities analysts predict that Illumina will post 4.51 EPS for the current year.

Insider Buying and Selling at Illumina

In related news, insider Scott M. Davies sold 323 shares of the firm’s stock in a transaction dated Friday, December 12th. The stock was sold at an average price of $136.09, for a total transaction of $43,957.07. Following the sale, the insider owned 17,887 shares of the company’s stock, valued at $2,434,241.83. This trade represents a 1.77% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Scott Gottlieb bought 500 shares of the business’s stock in a transaction on Monday, November 3rd. The stock was bought at an average price of $122.13 per share, for a total transaction of $61,065.00. Following the purchase, the director directly owned 12,523 shares of the company’s stock, valued at $1,529,433.99. The trade was a 4.16% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. 0.17% of the stock is currently owned by company insiders.

Institutional Trading of Illumina

Several hedge funds have recently modified their holdings of the company. Rise Advisors LLC raised its stake in shares of Illumina by 173.6% during the 1st quarter. Rise Advisors LLC now owns 353 shares of the life sciences company’s stock worth $28,000 after acquiring an additional 224 shares in the last quarter. Parkside Financial Bank & Trust boosted its stake in Illumina by 65.7% in the second quarter. Parkside Financial Bank & Trust now owns 290 shares of the life sciences company’s stock valued at $28,000 after acquiring an additional 115 shares in the last quarter. Quent Capital LLC purchased a new position in Illumina in the third quarter worth $29,000. Quarry LP acquired a new position in shares of Illumina during the third quarter worth $32,000. Finally, Aster Capital Management DIFC Ltd acquired a new position in shares of Illumina during the third quarter worth $33,000. 89.42% of the stock is owned by hedge funds and other institutional investors.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.